Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Aom0315 in Healthy Subjects
NCT05650528Phase 1Completed
- Sponsor
- Amckaus PTY LTD
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aom0315 in ischemic stroke (3 arms), sponsored by Amckaus PTY LTD. Primary endpoints: The safety and tolerability of single-dose ascending of oral QG101-23-0 capsules and The safety and tolerability of multiple-dose ascending oral QG101-23-0 capsules. Started Mar 2023; status: completed.
02
Drugs
aom0315
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05650528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650528.